Companies › BicycleTx
4 active drug programs in 7 registered trials: 4 Phase 2, 3 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| nuzefatide pevedotin (BT5528) EphA2-targeting antibody-drug conjugate | EPHA2 | Phase 2 | Pancreatic Ductal Adenocarcinoma (PDAC); Advanced Solid Tumor Historically Known for High EphA2 Expression | Dec 2026 |
| Zelenectide pevedotin anti-NECTIN4 antibody-drug conjugate | NECTIN4 | Phase 2 | Metastatic Urothelial Cancer; Breast Cancer; Non-Small Cell Lung Cancer | Mar 2028 |
| BT7480 Bicyclic peptide targeting Nectin-4 | NECTIN4 | Phase 1 | Advanced Solid Tumor | Dec 2026 |
| BT8009 Bicyclic Toxin Conjugate (BTC) targeting Nectin-4-expressing malignancies | NECTIN4 | Phase 1 | Urinary Bladder Neoplasm | Jan 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05163041 | BT7480 | Phase 1 | Advanced Solid Tumor | Oncology | Dec 2026 |
| NCT04180371 | nuzefatide pevedotin (BT5528) | Phase 1 | Advanced Solid Tumor Historically Known for High EphA2 Expression | Oncology | Dec 2026 |
| NCT04561362 | BT8009 | Phase 1 | Urinary Bladder Neoplasm | Oncology | Jan 2027 |
| NCT06225596 | Zelenectide pevedotin | Phase 2 | Metastatic Urothelial Cancer | Oncology | Mar 2028 |
| NCT06840483 | Zelenectide pevedotin | Phase 2 | Breast Cancer | Oncology | Jun 2028 |
| NCT06933329 | Zelenectide pevedotin | Phase 2 | Non-Small Cell Lung Cancer | Oncology | Aug 2028 |
| NCT07450859 | nuzefatide pevedotin (BT5528) | Phase 2 | Pancreatic Ductal Adenocarcinoma (PDAC) | Oncology | Mar 2029 |
Cash of $470m on 2026-09-30; operating cash outflow about $209m a year; runway about 27 months at that burn, to Dec 2028; 3 of 4 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Tianjin ConjuStar Biologics Revolution Medicines IDEAYA Biosciences Replimune HRYZ Biotech
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.